Efectividad de la bupivacaína con triamcinolona versus triamcinolona en pacientes con tendinopatia del manguito rotador. Instituto Autónomo Hospital Universitario de Los Andes. Mérida, marzo - julio 2024 Effectiveness of bupivacaine with triamcinolone versus triamcinolone in patients with rotator cuff tendinopathy. Autonomous Institute Hospital Universitario de Los Andes. Merida, march - july 2024

Abstract

Objective: to compare the effectiveness of a combination therapy of bupivacaine with triamcinolone versus triamcinolone alone in patients with RCT. Methods: a randomized controlled experimental study was conducted. Participants were randomly assigned to receive a combination of bupivacaine and triamcinolone or triamcinolone alone. The primary outcome measure was pain relief and function, assessed using the Visual Analogue Scale and the qDASH scale respectively. Data were collected at baseline and assessments were conducted at 2 and 4 weeks. Results: Study determined that no differences were observed in the improvement of pain or functionality at 2 and 4 weeks, however, the combined therapy group showed a greater decrease of 30% in the impact on quality of life (qDASH) at 4 weeks (86% versus 50% p 0.038). Conclusion: No differences were observed in the improvement in pain or functionality at 2 and 4 weeks, however, the combined therapy group is more effective in reducing the impact on quality of life at 4 weeks. This therapy could be considered a viable option in clinical practice to improve the short-term outcomes of patients with this condition. Further studies with larger sample sizes and long-term follow-up are recommended to confirm these findings.RESUMENObjetivo: comparar la efectividad de una terapia combinada de bupivacaina con triamcinolona versus triamcinolona sola en pacientes con tendinitis del manguito rotador. Métodos: se realizó un estudio experimental controlado aleatorizado. Los participantes fueron asignados aleatoriamente para recibir una combinación de bupivacaina y triamcinolona o triamcinolona sola. La medida de resultado primaria fue el alivio del dolor y la funcionalidad, evaluadas mediante la Escala Visual Analógica y la escala qDASH respectivamente. Los datos se recopilaron al inicio del estudio y se realizaron evaluaciones a las dos y cuatro semanas. Resultados: el estudio determinó que no se observaron diferencias en la mejoría de dolor ni en funcionalidad a las dos y cuatro semanas, sin embargo, el grupo de terapia combinada mostró mayor disminución de 30% en la afectación de la calidad de vida (qDASH) a las 4 semanas (86% versus 50% p=0,038). Conclusión: no se observaron diferencias en la mejoría de dolor ni en funcionalidad a las dos y cuatro semanas, sin embargo, el grupo de terapia combinada es más eficaz para disminuir la afectación de la calidad de vida a las cuatro semanas. Esta terapia podría considerarse una opción viable en la práctica clínica para mejorar los resultados a corto plazo de los pacientes con esta afección. Se recomienda realizar más estudios con muestras de mayor tamaño y un seguimiento a largo plazo para confirmar estos hallazgos.ABSTRACTObjective: to compare the effectiveness of a combination therapy of bupivacaine with triamcinolone versus triamcinolone alone in patients with RCT. Methods: a randomized controlled experimental study was conducted. Participants were randomly assigned to receive a combination of bupivacaine and triamcinolone or triamcinolone alone. The primary outcome measure was pain relief and function, assessed using the Visual Analogue Scale and the qDASH scale respectively. Data were collected at baseline and assessments were conducted at 2 and 4 weeks. Results: Study determined that no differences were observed in the improvement of pain or functionality at 2 and 4 weeks, however, the combined therapy group showed a greater decrease of 30% in the impact on quality of life (qDASH) at 4 weeks (86% versus 50% p 0.038). Conclusion: No differences were observed in the improvement in pain or functionality at 2 and 4 weeks, however, the combined therapy group is more effective in reducing the impact on quality of life at 4 weeks. This therapy could be considered a viable option in clinical practice to improve the short-term outcomes of patients with this condition. Further studies with larger sample sizes and long-term follow-up are recommended to confirm these findings.Recibido: 10-10-2024Aceptado: 19-12-2024Publicado: 28-02-202